Predicting response to platinum chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) using a genomic signature for “BRCAness”: A phase II clinical trial of satraplatin in men with mCRPC who have progressed on docetaxel.
S. M. Seng
No relevant relationships to disclose
M. D. Galsky
Consultant or Advisory Role - Bristol-Myers Squibb; Foundation Medicine; GlaxoSmithKline; Pfizer
Research Funding - Celgene
C. Tsao
No relevant relationships to disclose
J. Li
No relevant relationships to disclose
P. G. Febbo
No relevant relationships to disclose
W. K. Oh
No relevant relationships to disclose